Sponsor:
Tr1X, Inc.
Code:
NCT06462365
Conditions
Hematologic Malignancy
GvHD
GVHD,Acute
GVHD, Chronic
Hematopoietic Stem Cell Transplant
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TRX103
Brief summary:
Conditions
Hematologic Malignancy
GvHD
GVHD,Acute
GVHD, Chronic
Hematopoietic Stem Cell Transplant
Study ID
NCT06462365
Start date
Apr 8, 2024
Status verified date
Oct, 2024
Completion date
Apr 15, 2027
Anticipated
Primary completion date
Apr 15, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
36 participants
Anticipated
Intervention Model
Sequential
Primary purpose
Prevention
Arms
experimental: TRX-103
Interventions
TRX103
Primary outcome measure
Central contacts
Locations
Dana-Farber Cancer Institute
Recruiting
Boston, Massachusetts, United States, 02215
Contacts
University of Minnesota
Recruiting
Minneapolis, Minnesota, United States, 55455
Contacts
Memorial Sloan Kettering Cancer Center
Recruiting
New York, New York, United States, 10065
Contacts
Fred Hutchinson Cancer Center
Recruiting
Seattle, Washington, United States, 98109
Contacts
Sponsor
Tr1X, Inc.
Last update posted
Apr 15, 2025
Last verified
Oct, 2024
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Tr1X, Inc. on 2025-04-15.